Bavarian Nordic gets FDA approval for chikungunya vaccine
Bavarian Nordic (OTCPK:BVNRY) has received FDA approval for its vaccine Vimkunya for the prevention of chikungunya. The virus-like particle, or VLP, vaccine is approved for people aged 12 and older.
TMCnet15h
Bavarian Nordic Receives U.S. FDA Approval of Chikungunya Vaccine for Persons Aged 12 and Older
COPENHAGEN, Denmark, February 14, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that the U.S. Food and Drug Administration (FDA) has approved VIMKUNYA™ (Chikungunya Vaccine, Recombinant) for ...
Valneva (0OB3) Gets a Buy from Kepler Capital
In a report released on February 12, Justine Telliez from Kepler Capital maintained a Buy rating on Valneva (0OB3 – Research Report), with a ...
PMLiVE5d
CHMP recommends Bavarian Nordic’s chikungunya vaccine for individuals aged from 12 years
The European Commission (EC) has already approved Valneva’s chikungunya vaccine Ixchiq for use in individuals aged 18 years ...
boerse-social6d
21st Austria weekly - Valneva, Palfinger Marine...
PALFINGER MARINE secures a major contract with the Finnish Meyer Turku shipyard to provide lifesaving appliances (LSA) for Royal Caribbean International’s fourth Icon Class ship, set to debut in 2027.